CSPC PHARMA (01093.HK) announced that it has signed an exclusive licensing agreement with BEIGENE for the group's 'Novel Methionine Adenosyltransferase 2A (MAT2A)' inhibitor (SYH2039), as well as any Pharmaceutical comprising or containing this compound for development, manufacturing, and commercialization globally.

According to the exclusive licensing agreement, CSPC PHARMA agrees to grant BEIGENE exclusive rights for global development, manufacturing, and commercialization of this compound and product. CSPC PHARMA will receive a total upfront payment of $0.15 billion and is entitled to receive up to $0.135 billion in potential development milestone payments and up to $1.55 billion in potential sales milestone payments, as well as tiered sales royalties calculated based on the annual net sales of the product.

It is reported that the aforementioned Pharmaceutical can effectively inhibit the growth of various types of MTAP-deficient tumor cells, including non-small cell lung cancer, glioma, esophagogastric cancer, pancreatic cancer, and bladder cancer, exhibiting excellent in vitro and in vivo activity, while also possessing good pharmacokinetic properties and safety, and has the potential to become a best-in-class anti-tumor drug. (js/k)

~